Sign In
Buy CCXI
$13.86
-0.140 (-1.00%)
At Close: Jul 31, 2026
ChemoCentryx to Host Virtual R&D Day on April 14, 2021
08:30am, Wednesday, 07'th Apr 2021
MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. E
ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
08:30am, Monday, 08'th Mar 2021
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company's Executive Vice President and Chief Finan
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2020 Results - Earnings Call Transcript
12:19am, Tuesday, 02'nd Mar 2021
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2020 Results - Earnings Call Transcript
ChemoCentryx (CCXI) Reports Q4 Loss, Misses Revenue Estimates
06:57pm, Monday, 01'st Mar 2021
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -34.38% and -51.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
04:05pm, Monday, 01'st Mar 2021
-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associate
ChemoCentryx to Present at Two Upcoming Investor Conferences
08:30am, Thursday, 25'th Feb 2021
MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two up
ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021
08:30am, Tuesday, 23'rd Feb 2021
MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released aft
-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan's eff
ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data
11:17am, Tuesday, 22'nd Dec 2020
ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.
MOUNTAIN VIEW, Calif. and ST. GALLEN, Switzerland, Dec. 21, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from the ACC
ChemoCentryx to Present at Two Upcoming Investor Conferences
08:30am, Thursday, 19'th Nov 2020
MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two up
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript
02:05am, Tuesday, 10'th Nov 2020
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript
ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights
04:05pm, Monday, 09'th Nov 2020
-- New Drug Application (NDA ) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing Authoriza
-- Study Showed T reatment with Avacopan A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group -- MOUNTA
ST. GALLEN, Switzerland and MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the European M
